Regeneron may be pressed by Sanofi weakness: BMO
BMO Capital analyst, Matthew Luchini, reiterated his Market Perform rating on shares of Regeneron Pharma (NASDAQ: REGN) on the belief that REGN could come under pressure following Sanofi’s
2Q results, which saw Dupixent sales of $28.6mn, below consensus ~$30mn and buyside expectations of ~$50mn.
The analyst stated “we believe REGN remains highly sensitive to Dupixent and the miss could cause investors to question the strength of the launch. Thus, we believe management commentary remains key and we will be looking for color on inventory and prescription fill rates/payor dynamics”.
No change to the price target of $484.
Leave a Comment
Awesome Investors 